Pharmaceutical companies Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) revealed that they will be collaborating on the development and commercialisation of ORGOVYX, the first oral gonadotropin-releasing hormone receptor antagonist for the treatment of adult patients with advanced prostate cancer.
The collaboration will see the companies develop and commercialize ORGOVYX and relugolix combination tablet and share profits and expenses in the U.S. and Canada, with Myovant receiving an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total of up to $4.2 billion.
The companies will begin co-promoting ORGOVYX for advanced prostate cancer in early 2021, with the companies sharing profits and expenses.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Pfizer will receive an exclusive option to commercialise the tablet in oncology outside of the US and Canada, and, if the option is exercised, Myovant will receive $50 million and be entitled to receive double-digit royalties on sales.
“Pfizer is the ideal partner for Myovant given its impressive capabilities and track record across both oncology and women’s health,” commented Lynn Seely, Myovant’s CEO.
“This transformative collaboration will significantly strengthen the upcoming launch of ORGOVYX and the potential launches of relugolix combination tablet in women’s health, while substantially enhancing our financial position and enabling us to expand our pipeline of potential new medicines,” Seely added.
Myovant shares are currently trading 21.32% higher premarket at $27.60, after closing at $22.80 on Christmas eve. Shares of Pfizer have seen a limited reaction to the news, gaining 0.40%.
